A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis
Objectives: There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translationa...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Osteoarthritis and Cartilage Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2665913121000704 |
| _version_ | 1831809638165643264 |
|---|---|
| author | Solveig Skovlund Groen Dovile Sinkeviciute Anne-Christine Bay-Jensen Christian S. Thudium Morten A. Karsdal Simon Francis Thomsen Sven Lindemann Daniela Werkmann Joseph Blair Line Mærsk Staunstrup Patrik Önnerfjord Lars Arendt-Nielsen Signe Holm Nielsen |
| author_facet | Solveig Skovlund Groen Dovile Sinkeviciute Anne-Christine Bay-Jensen Christian S. Thudium Morten A. Karsdal Simon Francis Thomsen Sven Lindemann Daniela Werkmann Joseph Blair Line Mærsk Staunstrup Patrik Önnerfjord Lars Arendt-Nielsen Signe Holm Nielsen |
| author_sort | Solveig Skovlund Groen |
| collection | DOAJ |
| description | Objectives: There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translational biomarker. Methods: A type II collagen specific neoepitope (T2CM) was identified by mass spectrometry and monoclonal antibodies were raised towards the epitope, employed in a chemiluminescence immunoassay. T2CM was assessed in bovine cartilage explants with or without MMP-13 inhibitor, and explant supernatants were analyzed by Western blot. T2CM was measured in plasma samples from one study (n = 48 patients) where OA patients were referred to total knee replacement (TKR). Additionally, T2CM was quantified in serum from OA patients receiving salmon calcitonin treatment (sCT) (n = 50) compared to placebo (n = 57). Results: The T2CM assay was technically robust (13/4 % inter/intra-variation) and specific for the type II collagen fragment cleaved by MMP-1 and -13. The MMP-13 inhibitor reduced the T2CM release from bovine cartilage explants receiving catabolic treatment. These results were confirmed by Western blot. In human end-stage OA patients (scheduled for TKR), the T2CM levels were elevated compared to moderate OA (p<0.004). The OA patients receiving sCT had lower levels of T2CM compared to placebo group after 1, 6, and 24 months of treatment (p = 0.0285, p = 0.0484, p = 0.0035). Conclusions: To our knowledge, T2CM is the first technically robust serological biomarker assay which has shown biological relevance in ex vivo models and OA cohorts. This suggests that T2CM may have potential as a translational biomarker for cartilage degradation. |
| first_indexed | 2024-12-22T20:43:35Z |
| format | Article |
| id | doaj.art-dbead7b88abd48ba819c5601d42f0785 |
| institution | Directory Open Access Journal |
| issn | 2665-9131 |
| language | English |
| last_indexed | 2024-12-22T20:43:35Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Osteoarthritis and Cartilage Open |
| spelling | doaj.art-dbead7b88abd48ba819c5601d42f07852022-12-21T18:13:16ZengElsevierOsteoarthritis and Cartilage Open2665-91312021-12-0134100207A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritisSolveig Skovlund Groen0Dovile Sinkeviciute1Anne-Christine Bay-Jensen2Christian S. Thudium3Morten A. Karsdal4Simon Francis Thomsen5Sven Lindemann6Daniela Werkmann7Joseph Blair8Line Mærsk Staunstrup9Patrik Önnerfjord10Lars Arendt-Nielsen11Signe Holm Nielsen12Immunoscience, Nordic Bioscience, Herlev, Denmark; Department of Biomedical Sciences, University of Copenhagen, Denmark; Corresponding author. Nordic Bioscience, Herlev Hovedgade 205–207, 2730, Herlev, Denmark.Immunoscience, Nordic Bioscience, Herlev, Denmark; Department of Clinical Sciences Lund, Lund University, Lund, SwedenImmunoscience, Nordic Bioscience, Herlev, DenmarkImmunoscience, Nordic Bioscience, Herlev, DenmarkImmunoscience, Nordic Bioscience, Herlev, DenmarkDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, DenmarkMerck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, GermanyImmunoscience, Nordic Bioscience, Herlev, DenmarkImmunoscience, Nordic Bioscience, Herlev, DenmarkDepartment of Clinical Sciences Lund, Lund University, Lund, SwedenCenter for Neuroplasticity and Pain (CNAP), SMI®, Department of Health Science and Technology, School of Medicine, Aalborg University, Aalborg, DenmarkImmunoscience, Nordic Bioscience, Herlev, Denmark; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, DenmarkObjectives: There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translational biomarker. Methods: A type II collagen specific neoepitope (T2CM) was identified by mass spectrometry and monoclonal antibodies were raised towards the epitope, employed in a chemiluminescence immunoassay. T2CM was assessed in bovine cartilage explants with or without MMP-13 inhibitor, and explant supernatants were analyzed by Western blot. T2CM was measured in plasma samples from one study (n = 48 patients) where OA patients were referred to total knee replacement (TKR). Additionally, T2CM was quantified in serum from OA patients receiving salmon calcitonin treatment (sCT) (n = 50) compared to placebo (n = 57). Results: The T2CM assay was technically robust (13/4 % inter/intra-variation) and specific for the type II collagen fragment cleaved by MMP-1 and -13. The MMP-13 inhibitor reduced the T2CM release from bovine cartilage explants receiving catabolic treatment. These results were confirmed by Western blot. In human end-stage OA patients (scheduled for TKR), the T2CM levels were elevated compared to moderate OA (p<0.004). The OA patients receiving sCT had lower levels of T2CM compared to placebo group after 1, 6, and 24 months of treatment (p = 0.0285, p = 0.0484, p = 0.0035). Conclusions: To our knowledge, T2CM is the first technically robust serological biomarker assay which has shown biological relevance in ex vivo models and OA cohorts. This suggests that T2CM may have potential as a translational biomarker for cartilage degradation.http://www.sciencedirect.com/science/article/pii/S2665913121000704BiomarkerExtracellular matrixCartilageType II collagenT2CM |
| spellingShingle | Solveig Skovlund Groen Dovile Sinkeviciute Anne-Christine Bay-Jensen Christian S. Thudium Morten A. Karsdal Simon Francis Thomsen Sven Lindemann Daniela Werkmann Joseph Blair Line Mærsk Staunstrup Patrik Önnerfjord Lars Arendt-Nielsen Signe Holm Nielsen A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis Osteoarthritis and Cartilage Open Biomarker Extracellular matrix Cartilage Type II collagen T2CM |
| title | A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| title_full | A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| title_fullStr | A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| title_full_unstemmed | A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| title_short | A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| title_sort | serological type ii collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis |
| topic | Biomarker Extracellular matrix Cartilage Type II collagen T2CM |
| url | http://www.sciencedirect.com/science/article/pii/S2665913121000704 |
| work_keys_str_mv | AT solveigskovlundgroen aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT dovilesinkeviciute aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT annechristinebayjensen aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT christiansthudium aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT mortenakarsdal aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT simonfrancisthomsen aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT svenlindemann aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT danielawerkmann aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT josephblair aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT linemærskstaunstrup aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT patrikonnerfjord aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT larsarendtnielsen aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT signeholmnielsen aserologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT solveigskovlundgroen serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT dovilesinkeviciute serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT annechristinebayjensen serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT christiansthudium serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT mortenakarsdal serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT simonfrancisthomsen serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT svenlindemann serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT danielawerkmann serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT josephblair serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT linemærskstaunstrup serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT patrikonnerfjord serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT larsarendtnielsen serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis AT signeholmnielsen serologicaltypeiicollagenneoepitopebiomarkerreflectscartilagebreakdowninpatientswithosteoarthritis |